Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacodynamic Comparison of Pitavastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease Treated With Dual Antiplatelet Therapy - The PORTO Trial

Next Previous
X
Search
Trial Profile

Pharmacodynamic Comparison of Pitavastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease Treated With Dual Antiplatelet Therapy - The PORTO Trial

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 20 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atorvastatin (Primary) ; Pitavastatin (Primary) ; Aspirin; Clopidogrel
  • Indications Coronary artery disease; Thrombosis
  • Focus Pharmacodynamics
  • Acronyms PORTO

    • Most Recent Events

    • 18 Nov 2015 Status changed from not yet recruiting to active, no longer recruiting as per results published in Circulation Journal
    • 06 Mar 2013 Planned end date changed from 1 Dec 2013 to 1 Dec 2017 as reported by ClinicalTrials.gov.
    • 06 Mar 2013 Planned initiation date changed from 1 Jul 2012 to 1 Jan 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top